Humana · Off Label NCCN · US health-plan appeal rights

Off Label NCCN denied as experimental or investigational by Humana?

Q: How long do I have to appeal a Humana Off Label NCCN denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

An experimental denial requires the appeal to cite the FDA approval (if any), peer-reviewed phase III data, and the recognised specialty-society guideline that supports the treatment for your indication.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Humana typically requires

Humana's specific coverage criteria for off label nccn are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Humana Oncology Pharmacy Prior Authorization Criteria (Medicare Advantage tied to CMS NCDs/LCDs)

The Humana angle on Off Label NCCN

## Why Humana Denied This Off-Label (NCCN-Supported) Drug as Experimental

Humana's experimental or investigational denial typically means the plan concluded that the drug lacks sufficient evidence of clinical benefit for your specific indication. For drugs used off-label with NCCN Compendium support, this conclusion is frequently challengeable: NCCN listings reflect systematic expert consensus review of published evidence, and many state insurance laws — as well as federal oncology coverage rules — require plans to cover NCCN-listed uses as a standard of care.

## Why This Is Appealable

NCCN category designations signal the level of evidence and consensus behind an off-label use. When Humana's experimental denial fails to address the applicable NCCN category for your drug and indication, the denial is internally inconsistent with policies that recognize NCCN listings. Additionally, if your plan is an ACA-compliant individual or small-group plan, state external-review statutes often independently mandate coverage of NCCN-supported oncology drugs regardless of formulary status.

## Federal Appeal Framework

Internal appeal: Submit within the timeframe on your EOB. Explicitly cite Humana's own coverage policy language on NCCN compendium use and ask which category of evidence Humana applied.
External review (ACA §2719): After a final internal denial, an Independent Review Organization (IRO) reviews the evidence independently. The standard window is approximately four months from final denial; expedited review (72-hour turnaround) is available when a delay would seriously jeopardize your health.
ERISA §503 (employer plans): Request the specific clinical evidence standard Humana used, and the identity of the reviewing clinician's specialty.

## Documentation to Gather

1. Diagnosis and staging — complete pathology and imaging confirming the exact disease type, subtype, and stage for which the drug is requested. 2. NCCN compendium printout — the current applicable listing from NCCN.org showing the category designation for this drug/indication; download the full page. 3. Peer-reviewed literature — your oncologist's selection of the key published studies supporting this use; the prescriber should summarize why the evidence supports clinical benefit in your case. 4. Prescriber medical-necessity letter — a detailed letter explaining why standard-of-care alternatives have been tried, failed, or are contraindicated per the chart, and why this agent is the appropriate next step. 5. Prior treatment history — dated records of all prior treatments with response assessments.

## Criteria-Mapping Structure

Request Humana's written experimental/investigational criteria and the specific evidence standard they applied. Then construct a point-by-point response: for each criterion Humana cited as unmet, provide the NCCN listing, the prescriber's clinical rationale, and the supporting literature. Attach the NCCN printout as Exhibit A and the prescriber letter as Exhibit B.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Humana appeals

Other insurers on Off Label NCCN

Aetna denied as experimental or investigational of Off Label NCCN

Other denial reasons for Humana Off Label NCCN

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.